In8 Bio, Inc. financial data

Symbol
INAB on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
Empire State Building, 350 5 Th Avenue, Suite 5330, New York, NY
State of incorporation
DE
Fiscal year end
December 31
Former names
Incysus Therapeutics, Inc. (to 9/20/2018)
Latest financial report
10-Q - Q3 2024 - Nov 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 426 % -40.1%
Debt-to-equity 40.6 % +66.6%
Return On Equity -197 % -29%
Return On Assets -105 % -27.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 72.5M shares +127%
Common Stock, Shares, Outstanding 46.8M shares +46.3%
Entity Public Float 22.7M USD +285%
Common Stock, Value, Issued 5K USD +25%
Weighted Average Number of Shares Outstanding, Basic 47.3M shares +50%
Weighted Average Number of Shares Outstanding, Diluted 47.3M shares +50%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 17.9M USD +10.2%
General and Administrative Expense 13.1M USD -8.57%
Operating Income (Loss) -32.2M USD -6.61%
Net Income (Loss) Attributable to Parent -31.9M USD -5.52%
Earnings Per Share, Basic -0.74 USD/shares +33.3%
Earnings Per Share, Diluted -0.74 USD/shares +33.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Other Assets, Current 177K USD -32.4%
Assets, Current 6.7M USD -59.5%
Property, Plant and Equipment, Net 3.08M USD -17.6%
Operating Lease, Right-of-Use Asset 4.12M USD +11.6%
Other Assets, Noncurrent 324K USD +27.1%
Assets 16M USD -39.1%
Accounts Payable, Current 1.14M USD +52%
Accrued Liabilities, Current 769K USD -68.5%
Liabilities, Current 3.64M USD -22.4%
Operating Lease, Liability, Noncurrent 3.34M USD +8.96%
Liabilities 7.38M USD -12.7%
Retained Earnings (Accumulated Deficit) -115M USD -38.1%
Stockholders' Equity Attributable to Parent 8.59M USD -51.6%
Liabilities and Equity 16M USD -39.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -7.92M USD -6.45%
Net Cash Provided by (Used in) Financing Activities -277K USD -151%
Net Cash Provided by (Used in) Investing Activities -71K USD +83.5%
Common Stock, Shares Authorized 490M shares 0%
Common Stock, Shares, Issued 46.8M shares +46.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -8.27M USD -12.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.26M USD -67.5%
Deferred Tax Assets, Gross 20.7M USD +36.5%
Operating Lease, Liability 4.26M USD +10.7%
Depreciation 958K USD +17%
Payments to Acquire Property, Plant, and Equipment 50K USD -86.5%
Lessee, Operating Lease, Liability, to be Paid 5.41M USD +9.66%
Operating Lease, Liability, Current 920K USD +17.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.42M USD +15.7%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.4M USD +15.6%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure +8.26%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.14M USD +5.94%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.22M USD +20.8%
Deferred Tax Assets, Operating Loss Carryforwards 2.7M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 891K USD +16%
Additional Paid in Capital 124M USD +22.4%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 19.6M USD +41.3%
Share-based Payment Arrangement, Expense 5.43M USD +34.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%